Biosimilar Regulation: Bringing the United States Up To Speed with Other Markets
2015
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Biosimilar Regulation: Bringing the United States Up To Speed with Other Markets
Authors
Published Date
2015
Publisher
Minnesota Journal of Law, Science & Technology
Type
Article
Abstract
In light of the expected end of patent terms for many large molecule drugs called biologics, there has been a rise in the development of biosimilars—non-branded, copycat versions of biologics. Unlike generic drugs, which are non-branded versions of small molecule chemical drugs, biosimilars are not identical to the biologic they reference, since biologics are derived from living organisms and are often injected into the patient, which makes them impossible to replicate perfectly. Despite their complexities, biologics exist to treat important diseases such as AIDS, Alzheimer’s, and cancer. In 2010, the Biologics Price Competition and Innovation Act (Biosimilars Act) was added to the Public Health Service Act (PHS Act), outlining the approval process and regulatory plan for biosimilars. The Food and Drug Administration (FDA) subsequently released six Draft Guidance Documents (Guidance Documents) to clarify some of the provisions in the Biosimilars Act and to define ambiguous terms and phrases. Although biosimilars have been an important treatment option in many countries for over twenty years, none have been approved in the United States. On March 15, 2015, the FDA approved Sandoz’s Zarxio after the FDA’s Oncological Drugs Advisory Committee recommended approval by the agency. However, on May 5, 2015, the Appeals Court for the Federal Circuit granted an injunction preventing Sandoz from selling Zarxio until further arguments are heard. The FDA may be progressing toward a more lenient view on biosimilar approvals; however, the court’s injunction indicates that the United States lags in its exploitation of biosimilars, and revisions to the current law will allow for a robust biosimilars market. Previous scholarship has outlined the barriers to biosimilar acceptance in the United States and acknowledged the potential benefit of higher approval rates. This Note analyzes the Biosimilars Act and the Guidance Documents, and proposes revisions to these documents and to the current structure of the insurance and health care systems in relation to biosimilars. These adaptations will allow the United States to improve access to key medical treatments across the country and catch up with other biosimilar markets.
Keywords
Description
Related to
Replaces
License
Collections
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Banthia, Vinita. (2015). Biosimilar Regulation: Bringing the United States Up To Speed with Other Markets. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/172964.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.